Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rhee, Moo-Yong | - |
dc.contributor.author | Baek, Sang Hong | - |
dc.contributor.author | Kim, Weon | - |
dc.contributor.author | Park, Chang Gyu | - |
dc.contributor.author | Park, Seung Woo | - |
dc.contributor.author | Oh, Byung-Hee | - |
dc.contributor.author | Kim, Sang-Hyun | - |
dc.contributor.author | Kim, Jae-Joong | - |
dc.contributor.author | Shin, Joon-Han | - |
dc.contributor.author | Yoo, Byung-Su | - |
dc.contributor.author | Rim, Se-Joong | - |
dc.contributor.author | Ha, Jong-Won | - |
dc.contributor.author | Doh, Joon Hyung | - |
dc.contributor.author | Ahn, Youngkeun | - |
dc.contributor.author | Chae, Jei Keon | - |
dc.contributor.author | Park, Jeong Bae | - |
dc.contributor.author | Kim, Soon-Kil | - |
dc.contributor.author | Kim, Cheol Ho | - |
dc.date.accessioned | 2021-09-05T00:49:09Z | - |
dc.date.available | 2021-09-05T00:49:09Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 1177-8881 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/96154 | - |
dc.description.abstract | Background: The study reported here compared the blood pressure (BP)-lowering efficacy of fimasartan alone with that of fimasartan/hydrochlorothiazide (HCTZ) combination in patients whose BP goal was not achieved after 4 weeks of treatment with once-daily fimasartan 60 mg. Methods: Patients with sitting diastolic blood pressure (siDBP) >= 90 mmHg with 4 weeks of once-daily fimasartan 60 mg were randomly assigned to receive either once-daily fimasartan 60 mg/HCTZ 12.5 mg or fimasartan 60 mg for 4 weeks. After 4 weeks, the dose was increased from fimasartan 60 mg/HCTZ 12.5 mg to fimasartan 120 mg/HCTZ 12.5 mg or from fimasartan 60 mg to fimasartan 120 mg if siDBP was >90 mmHg. Results: Of the 263 randomized patients, 256 patients who had available efficacy data were analyzed. The fimasartan/HCTZ treatment group showed a greater reduction of siDBP compared to the fimasartan treatment group at Week 4 (6.88 +/- 8.10 mmHg vs 3.38 +/- 7.33, P=0.0008), and the effect persisted at Week 8 (8.67 +/- 9.39 mmHg vs 5.02 +/- 8.27 mmHg, P=0.0023). Reduction of sitting systolic BP in the fimasartan/HCTZ treatment group was also greater than that in the fimasartan treatment group (at Week 4, 10.50 +/- 13.76 mmHg vs 5.75 +/- 12.18 mmHg, P=0.0069 and, at Week 8, 13.45 +/- 15.15 mmHg vs 6.84 +/- 13.57 mmHg, P=0.0007). The proportion of patients who achieved a reduction of siDBP. 10 mmHg from baseline and/or a mean siDBP. 90 mmHg after 4 weeks of treatment was higher in the fimasartan/HCTZ treatment group than in the fimasartan treatment group (53.6% vs 39.8%, P=0.0359). The overall incidence of adverse drug reaction was 11.79% with no significant difference between the treatment groups. Conclusion: The combination treatment of fimasartan and HCTZ achieved better BP control than fimasartan monotherapy, and had comparable safety and tolerance to fimasartan monotherapy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | DOVE MEDICAL PRESS LTD | - |
dc.subject | TO-MODERATE HYPERTENSION | - |
dc.subject | PLACEBO-CONTROLLED TRIAL | - |
dc.subject | PARALLEL-GROUP TRIAL | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | BLOOD-PRESSURE | - |
dc.subject | ANTIHYPERTENSIVE THERAPY | - |
dc.subject | KOREAN PATIENTS | - |
dc.subject | CARDIOVASCULAR EVENTS | - |
dc.subject | HYDROCHLOROTHIAZIDE | - |
dc.subject | MILD | - |
dc.title | Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Chang Gyu | - |
dc.identifier.doi | 10.2147/DDDT.S82098 | - |
dc.identifier.scopusid | 2-s2.0-84934956549 | - |
dc.identifier.wosid | 000355409500003 | - |
dc.identifier.bibliographicCitation | DRUG DESIGN DEVELOPMENT AND THERAPY, v.9, pp.2847 - 2854 | - |
dc.relation.isPartOf | DRUG DESIGN DEVELOPMENT AND THERAPY | - |
dc.citation.title | DRUG DESIGN DEVELOPMENT AND THERAPY | - |
dc.citation.volume | 9 | - |
dc.citation.startPage | 2847 | - |
dc.citation.endPage | 2854 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | TO-MODERATE HYPERTENSION | - |
dc.subject.keywordPlus | PLACEBO-CONTROLLED TRIAL | - |
dc.subject.keywordPlus | PARALLEL-GROUP TRIAL | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | BLOOD-PRESSURE | - |
dc.subject.keywordPlus | ANTIHYPERTENSIVE THERAPY | - |
dc.subject.keywordPlus | KOREAN PATIENTS | - |
dc.subject.keywordPlus | CARDIOVASCULAR EVENTS | - |
dc.subject.keywordPlus | HYDROCHLOROTHIAZIDE | - |
dc.subject.keywordPlus | MILD | - |
dc.subject.keywordAuthor | blood pressure | - |
dc.subject.keywordAuthor | antihypertensive | - |
dc.subject.keywordAuthor | angiotensin-converting enzyme inhibitor | - |
dc.subject.keywordAuthor | angiotensin-receptor blocker | - |
dc.subject.keywordAuthor | angiotensin II type 1 receptor | - |
dc.subject.keywordAuthor | renin-angiotensin-aldosterone system inhibitor | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.